

Supplementary Table 1. Baseline characteristics of population with no visible occlusion that received tenecteplase versus alteplase

Characteristic	Tenecteplase (n=247)	Alteplase (n=232)
Age (yr)	71 (59–82)	71 (59–80)
Female sex	110 (44.5)	103 (44.4)
Baseline NIHSS	7 (5–10)	6 (4–9)
Baseline NIHSS score categories		
<8	143 (57.9)	146 (62.9)
8–15	87 (35.2)	76 (32.8)
≥16	17 (6.9)	10 (4.3)
Type of enrolling center		
Primary stroke center	23 (9.3)	14 (6.0)
Comprehensive stroke center	224 (90.7)	218 (93.9)
Workflow times (min)		
Stroke symptom onset to hospital arrival	94 (60–152)	95 (60–142)
Stroke symptom onset to needle	137 (103–208)	144 (108–192)
Stroke symptom onset to randomisation	132 (96–202)	138 (99–184)
Door (hospital arrival) to needle (thrombolysis start)	38 (29–51)	40 (32–55)

Values are presented as median (interquartile range) or n (%).

NIHSS, National Institutes of Health Stroke Scale; ICA, internal carotid artery; MCA, middle cerebral artery; NA, not applicable.

Supplementary Table 2. Safety outcomes in patients who received tenecteplase vs. alteplase in no visible occlusion subgroup

Outcome	Tenecteplase (n=247)	Alteplase (n=232)	Unadjusted risk difference (95% CI)	Adjusted RR (95% CI)
Death within 90 days of randomization	19 (7.8)	19 (8.4)	-0.01 (-0.06 to 0.04)	0.86 (0.45 to 1.65)
24-h sICH*	6 (2.4)	5 (2.1)	0.00 (-0.02 to 0.03)	1.19 (0.36 to 3.93)
Any ICH on imaging	20 (8.1)	19 (8.3)	0.00 (-0.05 to 0.04)	0.93 (0.49 to 1.76)
Subarachnoid hemorrhage	6 (2.4)	7 (3.1)	-0.01 (-0.04 to 0.02)	0.79 (0.26 to 2.37)
Subdural hemorrhage	0 (0)	3 (1.3)	-	-
Intraventricular hemorrhage	6 (2.4)	3 (1.3)	-0.01 (-0.01 to 0.04)	1.87 (0.47 to 7.48)
HI1 (scattered small petechia) [†]	2 (0.9)	4 (1.6)	-0.01 (-0.01 to 0.03)	1.66 (0.30 to 9.31)
HI2 (confluent petechia) [†]	6 (2.4)	6 (2.6)	0.00 (-0.03 to 0.03)	0.95 (0.30 to 2.95)
PH1 (hematoma occupying <30% of infarct with no substantive mass effect) [†]	7 (2.8)	4 (1.8)	-0.01 (-0.02 to 0.04)	1.64 (0.48 to 5.61)
PH2 (hematoma occupying <30% of infarct with obvious mass effect) [†]	2 (0.8)	2 (0.9)	0.00 (-0.02 to 0.02)	0.73 (0.08 to 6.37)
rPH1 (hematoma outside infarcted tissue without mass effect) [†]	2 (0.8)	1 (0.4)	0.00 (-0.01 to 0.01)	2.55 (0.18 to 36.37)
rPH2 (hematoma outside infarcted tissue with obvious mass effect) [†]	0 (0)	1 (0.4)	0.00 (-0.01 to 0.00)	-
Extracranial bleeding requiring blood transfusions	0 (0)	0 (0)	-	-
Orolingual angioedema	3 (1.2)	3 (1.3)	0.00 (-0.02 to 0.02)	0.99 (0.20 to 5.03)

Values are presented as n (%), unless otherwise indicated.

sICH, symptomatic intracerebral hemorrhage; ICH, intracranial hemorrhage; HI1, hemorrhagic infarction type 1; HI2, hemorrhagic infarction type 2; PH1, parenchymal hematoma type 1; PH2, parenchymal hematoma type 2; CI, confidence interval; RR, relative risk; -, not computable; NA, not applicable.

*Defined as any intracerebral hemorrhage that was temporally related to or directly responsible for decline in patient's clinical status; [†]Subclassification based on Heidelberg Bleeding Classification.